Relationship Between Metabolic DysfunctionAssociated Steatotic Liver Disease and Lipoprotein (a) and Other Biomarkers

被引:0
|
作者
Rossi, Felipe A. Munoz [1 ]
Agudelo, Juanita Salazar [2 ]
Castro, Nestor Israel Quinapanta [3 ]
Mosquera, Sofia Z. [2 ]
Fajardo, Maria Clara Mejia [4 ]
Lopez, Edgar Dario Mosquera [5 ]
Olarte, Jonathan Dany Espitia [1 ]
Medina, Maria Andrea Figueroa [6 ]
Simancas, Edwin Zuniga [7 ]
Osuna, Luis Fernando Saldarriaga [8 ]
机构
[1] Univ Nacl Colombia, Internal Med, Bogota, Colombia
[2] CES Clin, Emergency Med, Medellin, Colombia
[3] Reg Autonomous Univ Andes, Res & Biostat, Ambato, Ecuador
[4] Cooperat Univ Colombia, Gen Med, Medellin, Colombia
[5] Univ Cent Ecuador, Gen Med, Quito, Ecuador
[6] Libre Univ Colombia, Gen Med, Barranquilla, Colombia
[7] Sinu Univ, Cardiovasc & Metab Ctr, Gen Clin Caribbean, Blas Lezo Clin,Internal Med, Cartagena, Colombia
[8] Univ Nacl Colombia, Bogota, Colombia
关键词
non-alcoholic fatty liver disease; gamma glutamyl transferase (ggt); nash and steatosis; high-density lipoproteins (hdl-c); lipoprotein (a); INSULIN-RESISTANCE; RISK; STEATOHEPATITIS; EPIDEMIOLOGY; ASSOCIATION;
D O I
10.7759/cureus.63019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Metabolic dysfunction -associated steatotic liver disease (MASLD) primarily affects the adult population and is closely related to obesity. The most severe form of MASLD, metabolic dysfunctionassociated steatohepatitis (MASH), can progress to liver fibrosis. While lipoprotein(a) (Lp(a)) is known to be associated with cardiovascular disease, its relationship with MASLD remains unclear. This study aims to determine the prevalence of MASLD in ambulatory patients and to explore the association between Lp(a) levels and advanced liver damage. Methods: This retrospective cross-sectional study included 130 patients older than 18 years seen in a healthcare center in Medellin, Colombia, between April 2023 and May 2024. Sociodemographic, clinical, and specific biomarker data were collected. Patients with cirrhosis, previous liver disease, frequent alcohol consumption, cancer, and other severe conditions were excluded. Continuous variables were analyzed using Student's t -tests or Mann -Whitney tests according to their distribution, and categorical variables were analyzed using contingency tables and chi-square tests. Results: Of the 130 patients, 57.9% (n=73) had MASLD, with a higher prevalence in patients with obesity (80%, n=32). Lp(a) levels were abnormally high in 43.1% (n=31) of patients; however, a weak but significant inverse correlation was found between Lp(a) levels and the Fibrosis -4 (FIB -4) score, which is used to assess the severity of liver fibrosis. Patients with MASLD had significantly lower high -density lipoprotein (HDL) and vitamin D levels, and higher levels of gamma-glutamyl transferase (GGT). Conclusions: This study highlights the significant prevalence of MASLD in outpatients and its relationship with various biomarkers, including Lp(a), HDL, vitamin D, and GGT. Although the findings suggest a possible utility of Lp(a) as a biomarker in MASLD, longitudinal studies are needed to confirm these associations and clarify their role in liver disease progression. The study's limitations include its cross-sectional nature and potential selection bias, indicating the need for further research to validate these results.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] RECK and EGFR Signaling in Metabolic DysfunctionAssociated Steatotic Liver Disease
    Krause, Alexa
    Dashek, Ryan
    Flink, Jack
    Shryack, Grace
    Taylor, Christopher
    Meers, Grace
    Chandrasekar, Bysani
    Rector, R. Scott
    OBESITY, 2023, 31 : 217 - 218
  • [2] THE ROLE OF MICRORNA 122 IN METABOLIC DYSFUNCTIONASSOCIATED STEATOTIC LIVER DISEASE
    Tran, Khang
    Devaskar, Sherin
    Ghosh, Shubhamoy
    Calkins, Kara
    HEPATOLOGY, 2024, 80 : S88 - S89
  • [3] Barriers to Exercise in Patients With Metabolic DysfunctionAssociated Steatotic Liver Disease: A Patient Survey
    Deshpande, Kedar
    Olynyk, John
    Ayonrinde, Oyekoya
    Nosaka, Kazunori
    JOURNAL OF CLINICAL MEDICINE RESEARCH-CANADA, 2024, 16 (2-3): : 94 - 105
  • [4] PUM1 KNOCKDOWN AGGRAVATES LIPID DEPOSITION IN METABOLIC DYSFUNCTIONASSOCIATED STEATOTIC LIVER DISEASE
    Wan, Zhiping
    Cai, Xiang
    Liu, Xiaoquan
    Yang, Xiaoan
    Chen, Haoqi
    Deng, Hong
    HEPATOLOGY, 2024, 80 : S45 - S45
  • [5] Body Composition in Patients With Metabolic Dysfunctionassociated Steatotic Liver Disease: Impact of Body Surface Area
    Onishi, Saori
    Fukuda, Akira
    Matsui, Masahiro
    Ushiro, Kosuke
    Nishikawa, Tomohiro
    Asai, Akira
    Kim, Soo Ki
    Nishikawa, Hiroki
    IN VIVO, 2024, 38 (04): : 1917 - 1926
  • [6] VIRAL HEPATITIS WITH CONCURRENT METABOLIC DYSFUNCTIONASSOCIATED STEATOTIC LIVER DISEASE IS A SUBGROUP AT HIGH RISK FOR ADVANCED FIBROSIS
    Kim, David S.
    Le, Alexander
    Ismail, Mohamed
    Abboud, Yazan
    Khan, Wajiha
    Pyrsopoulos, Nikolaos T.
    Kim, Hyunseok
    Hajifathalian, Kaveh
    GASTROENTEROLOGY, 2024, 166 (05) : S1565 - S1566
  • [7] HUMAN HEPATIC 3D SPHEROIDS AS A MODEL FOR METABOLIC DYSFUNCTIONASSOCIATED STEATOTIC LIVER DISEASE ( MASLD)
    Choi, Mi-Sun
    Kim, Soojin
    Jegal, Hyun
    Lee, Ga-Won
    Oh, Jungh-Hwa
    HEPATOLOGY, 2024, 80 : S44 - S45
  • [8] STREPTOCOCCUS SALIVARIUS MITIGATES METABOLIC DYSFUNCTIONASSOCIATED STEATOTIC LIVER DISEASE BY MODULATING NLRP3 INFLAMMASOME PATHWAY
    Kim, Jeong Su
    Song, Seol Hee
    Park, JeongHa
    Kwon, Young Seok
    Kim, Dong Joon
    HEPATOLOGY, 2024, 80 : S62 - S63
  • [9] A RAT MODEL FOR METABOLIC DYSFUNCTIONASSOCIATED FATTY LIVER DISEASE
    Tsuchishima, Mutsumi
    Tsutsumi, Mikihiro
    George, Joseph
    HEPATOLOGY, 2023, 78 : S1064 - S1064
  • [10] CIRCULATING AND LIVER TISSUES EMILIN1 LEVELS ARE REDUCED AND ASSOCIATED WITH METABOLIC DYSFUNCTIONASSOCIATED STEATOTIC LIVER DISEASE IN PATIENTS AND MICE MODELS
    Wang, Xiaomei
    Ji, Huifan
    Niu, Junqi
    HEPATOLOGY, 2024, 80 : S22 - S22